Precision Biosciences (DTIL) Common Equity (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Common Equity of $76.1 million for Q1 2026, up 54.25% year-over-year from $49.3 million in Q1 2025, and down 17.5% quarter-over-quarter from $92.2 million in Q4 2025.
Precision Biosciences (DTIL) Common Equity (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Common Equity for 9 consecutive years, with $76.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 54.25% year-over-year to $76.1 million; the TTM figure through Mar 2026 stood at $76.1 million (up 54.25% YoY), while the FY2025 annual figure was $92.2 million, up 63.58% from the prior year.
- Common Equity eased to $76.1 million in Q1 2026 per DTIL's latest filing, from $92.2 million in the prior quarter.
- Across five years, Common Equity topped out at $103.0 million in Q2 2022 and bottomed at $16.6 million in Q3 2025.
- Historically, Common Equity has averaged $55.4 million across 5 years, with a median of $56.4 million in 2024.
- Annual changes were most pronounced in 2024 — Common Equity jumped 198.99% — and 2025, when it tumbled 74.36%.
- Precision Biosciences' Common Equity stood at $60.4 million in 2022, then slumped by 68.79% to $18.9 million in 2023, then surged by 198.99% to $56.4 million in 2024, then jumped by 63.58% to $92.2 million in 2025, then decreased by 17.5% to $76.1 million in 2026.
- Business Quant data shows DTIL's Common Equity at $76.1 million in Q1 2026, $92.2 million in Q4 2025, and $16.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 9.79 Bn |
| 10 | Precision Biosciences | 224.69 Mn | 137.15 Mn | - | 45.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.29 Mn |
| Mar 31, 2026 | 76.10 Mn |
| Dec 31, 2025 | 92.25 Mn |
| Sep 30, 2025 | 16.63 Mn |
| Jun 30, 2025 | 34.05 Mn |
| Mar 31, 2025 | 49.34 Mn |
| Dec 31, 2024 | 56.39 Mn |
| Sep 30, 2024 | 64.87 Mn |
| Jun 30, 2024 | 74.71 Mn |
| Mar 31, 2024 | 37.21 Mn |
| Dec 31, 2023 | 18.86 Mn |
| Sep 30, 2023 | 29.06 Mn |
| Jun 30, 2023 | 34.04 Mn |
| Mar 31, 2023 | 40.18 Mn |
| Dec 31, 2022 | 60.43 Mn |
| Sep 30, 2022 | 84.38 Mn |
| Jun 30, 2022 | 103.02 Mn |
| Mar 31, 2022 | 69.66 Mn |
| Dec 31, 2021 | 91.17 Mn |
| Sep 30, 2021 | 101.44 Mn |